RIVM expands HPV vaccination programme: girls and boys protected from six types of cancer with one vaccine Now not only girls, but also boys will have the opportunity to protect themselves from cancer caused by HPV.
Better monitoring of RSV thanks to new European project RIVM and Nivel contribute to building a European RSV monitoring network. Through the network, European health institutions and laboratories will exchange data on the spread of RSV. This will help us to better monitor the virus.
Can you solve a medical mystery? During World Antibiotic Awareness Week 2019, RIVM has set up an escape room in one of busiest shopping malls in the Netherlands.
State Secretary Blokhuis: boys will also be vaccinated against HPV virus The vaccine against the HPV human papillomavirus virus will also become available for boys.
Slightly fewer adult smokers In 2018, 22.4 per cent of the Dutch adult population indicated they were occasional smokers.
Research: HPV vaccine is safe RIVM research shows no causal link between the vaccine against cervical cancer (HPV) and long-term fatigue symptoms in girls.
Vaccination rate again drops slightly, HPV vaccination rate drops considerably The vaccination rate for vaccines included in the National Immunisation Programme has dropped slightly by about 1 percent.
Alertness about the Zika virus still needed for pregnant women Since May 2015, there has been a Zika virus outbreak in South and Central America, including the Caribbean. The Zika virus can cause birth defects, including microcephaly (small head size).
Guus Velders in Nature's "Ten people that mattered this year" Researcher Dr Guus Velders of RIVM has made the Nature top-10 list of 2016. This means that, according to Nature, he was one of the 10 most influential scientists in 2016.
RIVM research basis for historic climate agreement on HFCs Scientific research by RIVM’s Guus Velders stood partly at the basis of the HFC global climate agreement.